![Supplements Slow Late-Stage Age-related Macular Degeneration Progression Supplements Slow Late-Stage Age-related Macular Degeneration Progression](https://images.medindia.net/health-images/1200_1000/calcium-supplements-linked-to-dementia-risk-in-older-women.jpg)
Supplements slow disease progression during late stage of "dry" age-related macular degeneration
Go to source).
AREDS2 Supplements Show Promise in Slowing Late-Stage AMD Progression
The researchers reviewed original retinal scans from participants in the Age-Related Eye Disease Studies (AREDS and AREDS2) and observed that the antioxidant supplement slowed the expansion of geographic atrophy regions towards the central foveal region of the retina. The study was published in the journal Ophthalmology.‘Antioxidant supplements can slow vision loss in late-stage Age-related Macular Degeneration by 55% over three years. #visioncare #medindia’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
“We’ve known for a long time that AREDS2 supplements help slow the progression from intermediate to late AMD. Our analysis shows that taking AREDS2 supplements can also slow disease progression in people with late dry AMD,” said Tiarnan Keenan, M.D., Ph.D., of NIH’s National Eye Institute (NEI) and lead author of the study. “These findings support the continued use of AREDS2 supplements by people with late dry AMD.” ![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Efficacy of AREDS and AREDS2 Supplements
In their new analysis, the researchers reviewed the original retinal scans of participants in the AREDS (total 318 participants, 392 eyes) and AREDS2 (total 891 participants, 1210 eyes) trials who developed dry AMD, calculating the position and expansion rate of their regions of geographic atrophy. For those people who developed geographic atrophy in their central vision, the supplements had little benefit. But for the majority who developed geographic atrophy far from the fovea, the supplements slowed the rate of expansion towards the fovea by approximately 55% over an average of three years.In early and intermediate AMD, the light-sensing retina at the back of the eye develops small yellow deposits of fatty proteins called drusen. When the disease progresses to the late stage, people can develop leaky blood vessels (“wet” AMD) or can lose regions of light-sensitive cells in the retina (“dry” AMD). The geographic atrophy in these regions slowly expands over time, causing people to progressively lose their central vision.
The original AREDS trial found that a supplement formula containing antioxidants (vitamin C, E, and beta-carotene), along with zinc and copper, could slow progression of intermediate to late-stage AMD. The subsequent AREDS2 trial found that substituting the antioxidants lutein and zeaxanthin for beta-carotene improved the efficacy of the supplement formula and eliminated certain risks. At the time, neither trial detected any further benefit once participants had developed late-stage disease.
However, that original analysis did not account for a phenomenon in the dry form of late AMD called “foveal sparing.” While all regions of the retina are sensitive to light, the region that gives us the highest acuity central vision is called the fovea. Many people with dry AMD first develop geographic atrophy outside this foveal region, and they only lose their central vision when the geographic atrophy regions expand into the foveal area.
Advertisement
Reference:
- Supplements slow disease progression during late stage of “dry” age-related macular degeneration - (https://www.nih.gov/news-events/news-releases/supplements-slow-disease-progression-during-late-stage-dry-age-related-macular-degeneration)
Advertisement